FCCC LOGO Faculty Publications
Mutation Testing and Adjuvant Systemic Therapy in Cutaneous Melanoma
J Natl Compr Canc Netw. 2019 May;17(5.5) :615-617
Back to previous list
Abstract
According to Dr. Anthony J. Olszanski, the most significant updates to the treatment of cutaneous melanoma include the recently published results of MSLT-II, which demonstrated that ultrasound-guided follow-up can be performed rather than a complete lymph node dissection, improving morbidity in patients with sentinel node metastases while not adversely affecting survival. In the adjuvant setting, the PD-1 inhibitors nivolumab and pembrolizumab are now FDA-approved, in addition to dabrafenib and trametinib, for patients with BRAF mutations.
Notes
Olszanski, Anthony J. NCCN Annual Conference on Improving the Quality, Effectiveness, and Efficiency of Cancer Care Mar 21-22, 2019 Orlando, FL Nccn 1540-1413 J Natl Compr Canc Netw. 2019 May 1;17(5.5):615-617. doi: 10.6004/jnccn.2019.5019.